Oral VC005 for moderate to severe eczema
Part of Skin clinical trials.
This study tests an investigational oral tablet (VC005) for adults with moderate to severe atopic dermatitis (eczema). It is for people whose eczema has not been controlled well enough with topical treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have had atopic dermatitis (eczema) for at least 1 year.
- Your eczema is moderate to severe (covering at least 10% of your body or a severity score of 3 or higher).
- You have tried topical treatments (creams or ointments) in the past year that did not work well enough or caused side effects.
- You are between 18 and 75 years old.
- You do not have certain medical conditions like a history of blood clots, herpes infections, or cancer (except for some minor skin cancers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new cream (CMS-D001) for people with moderate to severe eczema. Participants will receive either the study cream or a placebo (a cream with no active ingredient) to see if it helps reduce symptoms like itching and redness.
This trial tests an oral medication (capsule) for moderate to severe atopic dermatitis (eczema) that has not responded well to other treatments. The goal is to see if it can reduce symptoms like itching and skin inflammation.
This trial tests an oral pill called LW402 for people with moderate-to-severe atopic dermatitis (eczema). It aims to see if the drug is safe and effective at reducing skin symptoms.
This study tests a new medication called VC005 to treat atopic dermatitis (eczema)—a skin condition causing itching, redness, and inflammation. Researchers want to see if VC005 can safely reduce symptoms in people aged 12 and older with mild-to-moderate cases.
This study tests a new gel called VC005 to see if it safely reduces itching, redness, and irritation in people with atopic dermatitis (a chronic skin condition). You'll be randomly assigned to either the new gel or a placebo (inactive gel) and apply it to affected areas over several weeks.
This study tests a new medication (IBI3033) for people with moderate to severe atopic dermatitis (eczema) that hasn't responded well to creams. The goal is to see if it's safe and effective in reducing symptoms like itching and rash.
Hear when a new Moderate to Severe Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.